Ceres Nanosciences
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Revenues | 3.1m | 3.1m | 3.2m | 3.5m | 3.9m |
% growth | - | - | 3 % | 9 % | 11 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $2.5m | Angel | |
$250k | Grant | ||
$746k | Grant | ||
N/A | $500k | Grant | |
$980k | Grant | ||
$3.0m | Series A | ||
$8.5m | Series A | ||
$600k | Grant | ||
$230k | Grant | ||
$240k | Grant | ||
N/A | $8.2m | Grant | |
* | N/A | $5.0m | Early VC |
Total Funding | €28.0m |
Recent News about Ceres Nanosciences
EditCeres Nanosciences, Inc. specializes in developing advanced sample preparation tools designed to enhance the accuracy and reliability of diagnostic applications. The company's core product, Nanotrap particles, captures, concentrates, and preserves low abundance analytes from various sample types, ensuring precise analysis and diagnosis. Ceres Nanosciences serves clients in the healthcare and research sectors, including diagnostic laboratories, pharmaceutical companies, and academic institutions. Operating in the biotechnology market, the company employs a business model that generates revenue through the sale of its proprietary Nanotrap products and related diagnostic kits. By improving the performance of downstream analytical methods such as PCR, Western blot, and NGS, Ceres Nanosciences helps reduce sample processing time and eliminate false negatives, thereby enhancing the overall efficiency of diagnostic processes.
Keywords: Nanotrap, biomarkers, diagnostic tools, sample preparation, analyte concentration, healthcare, biotechnology, PCR, ELISA, infectious disease.